How we research pharma services vendors

How we categorize vendors

The 18 site categories are organized into four super-groups: Patient Access & Support, Commercialization & Market Access, Clinical, Regulatory & Evidence, and Supply Chain, Technology & Engagement. Category definitions are MECE (mutually exclusive, collectively exhaustive) for primary placement — every vendor has exactly one primary category — but a vendor may carry up to three secondary categories when its portfolio genuinely spans functions.

Primary category assignment reflects where a vendor makes most of its revenue and where it has earned a reputation, not where marketing claims suggest it competes. A vendor that built its business on hub services and later added a copay card module is a Patient Support Hub first, Copay & Affordability second — not equal weight in both.

We also distinguish between secondary categories and capability overlays. Secondary categories are reserved for real adjacent business lines that materially describe the company. Capability overlays are a narrower editorial device used for a few under-populated categories when a vendor has a clearly documented, dedicated offering but that lane is still not the vendor's home market.

Today, overlays are limited to five thin lanes: patient engagement, medical affairs/MSL support, field force/sales operations, managed markets / payer contracting, and clinical trial services. We do not infer those overlays from generic "full-service commercialization" copy alone. A vendor only receives one when the profile documents a named service line, explicit capabilities section, or similarly concrete evidence.

How we score and rank

Rankings and "best for" recommendations reflect editorial judgment informed by structured criteria. For every listicle or comparison, we evaluate vendors on:

• Capability depth — breadth of services, specialized tooling, therapeutic-area experience.
• Operating scale — number of manufacturer programs, patient volume, transaction throughput, geographic footprint.
• Client mix — disclosed manufacturer clients, concentration risk, biotech-vs-big-pharma balance.
• Track record — years in business, program longevity, public case studies, regulatory actions.
• Commercial fit — pricing model transparency, minimums, and fit for small-to-mid biotech launch teams vs. top-20 pharma.

"Best for" labels are narrower than overall rankings — a vendor can be #4 overall and still be the best choice for rare-disease launches or oncology buy-and-bill. Buyers should read the "best for" note, not just the rank.

Update cadence

Every profile shows a last updated date. Our baseline refresh cadence:

• Top-25 vendors — reviewed quarterly or on material news (M&A, leadership change, major program win/loss).
• All published vendors — reviewed at least annually for basic accuracy (services list, ownership, website, category placement).
• Articles and rankings — re-reviewed when the underlying market shifts (new CMS rule, PBM reform, PE transaction) or when a ranked vendor is acquired, exits a segment, or loses material clients.

If you see something out of date, the "Suggest a correction" link on every vendor page opens a direct email to the editor. We review every submission; corrections appear in the next update cycle with an edit note.

Editorial independence

Rx Almanac accepts sponsored content — clearly labeled as such — but sponsorship does not influence vendor rankings, category placement, or editorial coverage. Specifically:

• Sponsored placements never alter a vendor's rank in a listicle or its "best for" label.
• Featured-listing customers do not receive preferential editorial coverage. Their profiles follow the same evidence and sourcing standards as non-customers.
• Sponsored articles and comparisons are visually distinguished with a "Sponsored" label and sponsor name at the top of the page.
• The editor holds no equity, advisory relationships, or consulting engagements with vendors profiled on the site. Any future relationships will be disclosed on the relevant profile.

Known limitations

We publish our limitations so buyers can calibrate how they use the directory:

• US-first coverage. The current vendor set skews toward US-focused specialty pharmacy, hub services, and commercialization vendors. EU and APAC coverage is thinner and expanding.
• Conference-visibility bias. Seed sourcing favored companies that exhibit at Asembia AXSS, CBI, and similar conferences. Smaller startups and niche PBM-side vendors are under-represented; we are actively adding them.
• Private-company opacity. For PE-owned vendors, revenue, client count, and margin data are often not public. We flag what is disclosed and avoid fabricating precision.
• Temporal drift. Pharma services is a rapidly consolidating market. Rankings reflect the time of writing; read the published/updated date before acting on a recommendation.